New hope for lung cancer patients as trial tests promising drug against standard chemo
NCT ID NCT05870319
Summary
This study is comparing a new drug called SKB264 against standard chemotherapy for people with advanced non-small cell lung cancer. It's for patients whose cancer has a specific genetic change (EGFR mutation) and has continued to grow despite initial targeted therapy. The trial aims to see if SKB264 alone can better control cancer growth and improve survival compared to current standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.